HPV Vaccine – Transitioning from 4vHPV to 9vHPV

Tips to manage your HPV vaccine supply
For those providers who choose to implement 9-valent human papillomavirus (9vHPV) vaccine, but still have quadrivalent (4vHPV) stock in their office, doses of quadrivalent 4vHPV can be used to complete the series for patients who have received two doses of 4vHPV, or may be used in boys since the additional protection from 9vHPV will mostly benefit females.

ACIP recommends HPV vaccination for all boys and girls at age 11 or 12 years. Girls and boys can start the series at age 9 years. ACIP recommends vaccination through age 26 for females and through age 21 for males, if they were not previously vaccinated. Vaccination is also recommended through age 26 years for men who have sex with men and for immunocompromised persons (including those with HIV infection), if they were not previously vaccinated. Other males aged 22-26 years may be vaccinated. HPV vaccination for females is recommended with either bivalent (2vHPV), 4vHPV, or 9vHPV, and vaccination for males is recommended with either 4vHPV or 9vHPV. 2vHPV, 4vHPV4 and 9vHPV all protect against HPV 16 and 18, the types that cause about 66% of cervical cancers and the majority of other HPV-attributable cancers in the United States.

ACIP has not stated a preference for any of the HPV vaccines currently licensed in the United States. If clinicians do not know or do not have available the previously administered HPV vaccine product, any available HPV vaccine product may be used to continue or complete the series for females, and 2vHPV or 9vHPV may be used to continue or complete the series for males.

CDC has made HPV vaccination of adolescents a top priority since coverage rates for both males and females continue to lag well behind the Healthy People 2020 goal of 80% coverage. Providers should take advantage of the routine adolescent visit to immunize with pertussis (Tdap), Meningococcal and HPV vaccines. HPV vaccine should be promoted for what it is: a cancer prevention vaccine that saves lives.

Flu Vaccine Supply for 2015-16

Delay in FluMist shipping
MedImmune has notified the CDC of a shipping delay for their Live Attenuated Intranasal Influenza Vaccine FluMist. Doses of FluMist are not expected to be available until early-mid September. All other manufacturers of influenza vaccine are expected to have doses available sometime in August. Once influenza doses are available at McKesson, providers will be notified they may begin to place orders for flu vaccine. The CVP will do its best to get as much vaccine out as quickly as possible, but the majority of flu doses are not usually available until September and October. Providers should only order enough flu vaccine to meet their current needs and place multiple orders per month to better manage their inventory.